CMAB Biopharma and Shenzhen Fapon Biopharma announced a comprehensive strategic agreement for the development and manufacturing of an undisclosed biologic drug project.
According to the agreement, Fapon Biopharma will avail of the fully integrated CMC process development and manufacturing platform, the European QP audited product quality system and the experienced regulatory team in dual IND filings in both China and the United States at CMAB.
"Fapon Biotechnology is a leading supplier of raw materials and solutions for IVD reagent, which is well-known in the industry for its leading R&D technology and excellent product quality,” Dr. Lisheng Lu, Chief Scientist of Fapon Biopharma said.
"We are very excited and proud to be able to closely participate in this meaningful biologic drug development project of Fapon Biopharma,” Dr. Yongzhong Wang, CEO of CMAB Biopharma said. “The founding aspiration and goal of CMAB is to make our customers successful as quickly as possible. We are willing and confident to work with innovative biopharmaceutical companies such as Fapon Biopharma to overcome technical difficulties, reduce R&D costs, reach milestones quickly and of high quality, and create sustainable value for customers."